恒瑞医药：海曲泊帕乙醇胺片药品上市许可申请获国家药监局受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received a notice from the National Medical Products Administration (NMPA) regarding the acceptance of its drug listing application for Haequparib Ethanolamine Tablets, which are intended for the treatment of chemotherapy-induced thrombocytopenia in adult patients [2] Company Summary - The drug application is specifically aimed at addressing thrombocytopenia caused by chemotherapy, indicating a focus on oncology treatments [2] - The acceptance of the application marks a significant step for the company in expanding its product portfolio in the oncology sector [2]